National Cancer Institute (NCI): Lymphoma, T-Cell, Peripheral trials

The registry lists 31 Lymphoma, T-Cell, Peripheral studies with National Cancer Institute (NCI) as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 21Phase 2 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 1
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompletedNCT03905135Phase 1Results posted
• T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasCompletedNCT03049449Phase 1Results posted
• Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedNCT01445535Phase 1Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaCompletedNCT00131937Phase 2Results posted
• UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell LymphomasTerminatedNCT00082017Phase 2Results posted
• Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell LymphomasCompletedNCT00080535Phase 2Results posted
• Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaCompletedNCT00007345Phase 2Results posted
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)SuspendedNCT07055477Phase 1
• Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaActive, not recruitingNCT03922724Phase 2
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell LymphomaTerminatedNCT01445340Phase 1
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
• Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
• T-Cell Project: Epidemiologic ComponentCompletedNCT00705809
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
• 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell LymphomaTerminatedNCT00005950Phase 2
• 506U78 in Treating Patients With LymphomaCompletedNCT00005080Phase 2